Newfeed

Glenmark will be responsible for further developing, registering, and commercializing Envafolimab in India, Asia Pacific, Middle East and Africa, Russia, CIS, and Latin America. Jiangsu Alphamab and 3D Medicines will receive a low double digit Million US Dollar amount up to launch, additional triple

DUBLIN, Jan. 25, 2024 /PRNewswire/ — The “Global Building Technology and Service Business Model Innovation and Growth Opportunities” report has been added to ResearchAndMarkets.com’s offering. In this study, the analyst segments building technologies and services into buildi

Magazine made for you.

Featured:

No posts were found for provided query parameters.

Elsewhere: